APOBEC3 Proteins: From Antiviral Immunity to Oncogenic Drivers in HPV-Positive Cancers
Viruses · 2025
DOI: 10.3390/v17030436 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, 2025. Verfasst von Eliza Pizarro Castilha und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Genetics and Immunology, Department of Immunology, Parasitology and General Pathology, Center of Biological Sciences, State U…. Hauptthemen laut MEDLINE: Neoplasms, Papillomavirus Infections, APOBEC Deaminases, Papillomaviridae. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Coordenação de Aperfeicoamento de Pessoal de Nível Superior, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES).
Abstract (Originalsprache)
The human APOBEC superfamily consists of eleven cytidine deaminase enzymes. Among them, APOBEC3 enzymes play a dual role in antiviral immunity and cancer development. APOBEC3 enzymes, including APOBEC3A (A3A) and APOBEC3B (A3B), induce mutations in viral DNA, effectively inhibiting viral replication but also promoting somatic mutations in the host genome, contributing to cancer development. A3A and A3B are linked to mutational signatures in over 50% of human cancers, with A3A being a potent mutagen. A3B, one of the first APOBEC3 enzymes linked to carcinogenesis, plays a significant role in HPV-associated cancers by driving somatic mutagenesis and tumor progression. The A3A_B deletion polymorphism results in a hybrid A3A_B gene, leading to increased A3A expression and enhanced mutagenic potential. Such polymorphism has been linked to an elevated risk of certain cancers, particularly in populations where it is more prevalent. This review explores the molecular mechanisms of APOBEC3 proteins, highlighting their dual roles in antiviral defense and tumorigenesis. We also discuss the clinical implications of genetic variants, such as the A3A_B polymorphism, mainly in HPV infection and associated cancers, providing a comprehensive understanding of their contributions to both viral restriction and cancer development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular Genetics and Immunology, Department of Immunology, Parasitology and General Pathology, Center of Biological Sciences, State University of Londrina, Londrina 86057-970, Brazil.
- Leiden Academic Centre for Drug Research, Analytical Biosciences, Leiden University, P.O. Box 9502, 2311 EZ Leiden, The Netherlands.
- School of Cancer Sciences, Faculty of Medicine, University of Southampton, University Hospital Southampton, Tremona Road, Southampton SO16 6YD, UK.
- Institute for Life Sciences, University of Southampton, University Road, Southampton SO17 1BJ, UK.
- Polymorphism Research Laboratory, Department of Immunology, Parasitology and General Pathology, Center of Biological Sciences, State University of Londrina, Londrina 86057-970, Brazil.
ORCID-Profile: Eliza Pizarro Castilha, Rosalba Biondo, Timothy Robert Fenton, Karen Brajão de Oliveira
Förderung
- Coordenação de Aperfeicoamento de Pessoal de Nível Superior
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES)
Zitieren
APA
Castilha, E. P., Biondo, R., Trugilo, K. P., Fortunato, G. M., Fenton, T. R., & Oliveira, K. B. (2025). APOBEC3 Proteins: From Antiviral Immunity to Oncogenic Drivers in HPV-Positive Cancers. Viruses. https://doi.org/10.3390/v17030436
Vancouver
Castilha EP, Biondo R, Trugilo KP, Fortunato GM, Fenton TR, Oliveira KB. APOBEC3 Proteins: From Antiviral Immunity to Oncogenic Drivers in HPV-Positive Cancers. Viruses. 2025. doi:10.3390/v17030436
BibTeX
@article{Castilha2025,
author = {Castilha, Eliza Pizarro and Biondo, Rosalba and Trugilo, Kleber Paiva and Fortunato, Giulia Mariane and Fenton, Timothy Robert and Oliveira, Karen Brajão de},
title = {APOBEC3 Proteins: From Antiviral Immunity to Oncogenic Drivers in HPV-Positive Cancers},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17030436}
}
EUVIMED